|
PFE's Net Income Growth by Quarter and Year
Pfizer Inc's Net Income results by quarter and year
Select the Comparisons :
|
|
Select the Ratio:
|
|
PFE Net Income (in millions $) |
FY 2023 |
FY 2022 |
FY 2021 |
FY 2020 |
IV Quarter |
December |
-3,360.00
|
5,003.00
|
3,391.00
|
605.00
|
III Quarter |
September |
-2,376.00
|
8,623.00
|
8,159.00
|
2,202.00
|
II Quarter |
June |
2,338.00
|
9,911.00
|
5,589.00
|
3,434.00
|
I Quarter |
March |
5,556.00
|
7,870.00
|
4,886.00
|
3,410.00
|
FY |
|
2,158.00
|
31,407.00
|
22,025.00
|
9,651.00
|
PFE Net Income fourth quarter 2023 Y/Y Growth Comment |
Pfizer Inc in the fourth quarter 2023 recorded net loss of $ -3,360.00 millions.
Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 8 other companies have achieved higher Net Income growth. While Pfizer Inc' s Net Income no change of % ranks overall at the positon no. 438 in the fourth quarter 2023.
|
PFE Net Income ( Y/Y Growth %) |
2023
|
2022 |
2021 |
2020 |
IV Quarter |
December |
- |
47.54 % |
460.5 % |
- |
III Quarter |
September |
- |
5.69 % |
270.53 % |
-71.34 % |
II Quarter |
June |
-76.41 % |
77.33 % |
62.75 % |
-32.08 % |
I Quarter |
March |
-29.4 % |
61.07 % |
43.28 % |
-12.32 % |
FY |
|
-93.13 % |
42.6 % |
128.21 % |
-40.8 % |
PFE Net Income (Quarter on Quarter Growth %) |
2023
|
2022 |
2021 |
2020 |
IV Quarter |
December |
- |
-41.98 % |
-58.44 % |
-72.52 % |
III Quarter |
September |
- |
-13 % |
45.98 % |
-35.88 % |
II Quarter |
June |
-57.92 % |
25.93 % |
14.39 % |
0.7 % |
I Quarter |
March |
11.05 % |
132.08 % |
707.6 % |
- |
FY (Year on Year) |
|
-93.13 % |
42.6 % |
128.21 % |
-40.8 % |
Net Income Y/Y Growth Statistics |
High |
Average |
Low |
274.98 % |
21.11 % |
-93.13 % |
(Jul 01 2018) |
|
(Dec 31 2023) |
|
Net Income Y/Y Growth Statistics |
High |
Average |
Low |
274.98 % |
21.11 % |
-93.13 % |
(Jul 01 2018) |
|
(Dec 31 2023) |
|
Net Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023 |
Pfizer Inc's Q/Q Net Income Growth
Net Income Q/Q Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
PFE's IV. Quarter Q/Q Net Income Comment |
Current accomplishment of -3,360.00 millions by Pfizer Inc appear even more unfavourable considering the net loss -2,376.00 millions a quarter before.
Within Major Pharmaceutical Preparations industry Pfizer Inc achieved highest sequential Net Income growth. While Pfizer Inc's Net Income growth quarter on quarter, overall rank is . |
|
|
Net Income Q/Q Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
PFE's IV. Quarter Q/Q Net Income Comment |
Current accomplishment of -3,360.00 millions by Pfizer Inc come out even less good considering the -2,376.00 millions net loss in the previous quarter.
Within Major Pharmaceutical Preparations industry Pfizer Inc achieved highest sequential Net Income growth. While Pfizer Inc's Net Income growth quarter on quarter, overall rank is . |
|
Pfizer Inc's 12 Months Net Income Growth Year on Year
Net Income TTM Growth |
12 Months Ending (Dec 31 2023) |
12 Months Ending (Oct 01 2023) |
12 Months Ending (Jul 02 2023) |
12 Months Ending (Apr 02 2023) |
12 Months Ending (Dec 31 2022) |
Cumulative Net Income 12 Months Ending |
$ 2,158.00 |
$ 10,521.00 |
$ 21,520.00 |
$ 29,093.00 |
$ 31,407.00 |
Y / Y Net Income Growth (TTM) |
-93.13 % |
-64.69 % |
-26.63 % |
16.33 % |
42.6 % |
Year on Year Net Income Growth Overall
Ranking |
# 188 |
# 247 |
# 396 |
# 213 |
# 271 |
Seqeuential Net Income Change (TTM) |
-79.49 % |
-51.11 % |
-26.03 % |
-7.37 % |
5.41 % |
Seq. Net Income Growth (TTM) Overall
Ranking |
# 438 |
# 702 |
# 1175 |
# 1093 |
# 519 |
Cumulative Net Income growth
Comment |
Pfizer Inc's cumulative 12 months Net Income continue to drop, but on the faster rate at -93.13% year on year, at Dec 31 2023 compare to the -64.69% decrease at Oct 01 2023. If the Pfizer Inc's fiscal year would end at Dec 31 2023, annual Net Income would be $2,158 millions.
Among companies within the Healthcare sector 14 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 188, from total ranking in previous quarter at 247. |
Net Income TTM Q/Q Growth Statistics |
High |
Average |
Low |
274.98 % |
21.11 % |
-93.13 % |
|
|
|
|
|
Net Income TTM Y/Y Growth Statistics |
High |
Average |
Low |
274.98 % |
21.11 % |
-93.13 % |
|
|
|
Net Income TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 9 |
Sector |
# 36 |
S&P 500 |
# 438 |
|
Cumulative Net Income growth
Comment |
Pfizer Inc's cumulative 12 months Net Income continue to drop, but on the faster rate at -93.13% year on year, at Dec 31 2023 compare to the -64.69% decrease at Oct 01 2023. If the Pfizer Inc's fiscal year would end at Dec 31 2023, annual Net Income would be $2,158 millions.
Among companies within the Healthcare sector 14 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 188, from total ranking in previous quarter at 247. |
Net Income TTM Q/Q Growth Statistics |
High |
Average |
Low |
274.98 % |
21.11 % |
-93.13 % |
|
|
|
Net Income TTM Y/Y Growth Statistics |
High |
Average |
Low |
274.98 % |
21.11 % |
-93.13 % |
|
|
|
Net Income TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 9 |
Sector |
# 36 |
S&P 500 |
# 438 |
|